サンプル依頼リスト カート
  • English
  • Korean
表紙：心臓移植の世界市場-2023年～2030年
市場調査レポート
商品コード
1374804

心臓移植の世界市場-2023年～2030年

Global Heart Transplant Market -2023-2030

出版日
ページ情報
英文 190 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
心臓移植の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

故障したり損傷したりした心臓の代わりに、健康なドナーの心臓を患者の体内に移植することは、困難かつ救命的な医療手術です。末期心不全や重篤な心疾患を持つ患者に対する治療の選択肢としての心臓移植は、多くの理由から進歩し続け、成功を収めています。手術方法、免疫抑制剤、移植後のケアの改善により、心臓移植を受けた患者は、現在、より良い生存率と生活の質を享受しています。患者もヘルスケア専門家も、この手術の成功に意欲を燃やしています。

臓器提供の啓発キャンペーン、臓器の入手・保存方法の改善、より厳格な基準を満たしたドナーの活用などのプログラムを通じてドナープールを拡大する努力の結果、ドナー心臓の入手可能性は高まっています。免疫システムに関する知識の進歩や、より強力な免疫抑制剤の開発により、臓器拒絶反応の危険性は減少し、移植を受けた患者の長期予後も改善しています。

ダイナミクス

調査活動の増加

心臓移植の調査範囲を拡大することは、この救命治療の成果と利用しやすさを大きく向上させる可能性を秘めています。研究の結果、ドナーの心臓の寿命を延ばす高度な臓器保存法が開発されるかもしれないです。潜在的な臓器提供者の数が増え、移植が困難になる可能性を減らすことができます。

2022年12月、IITカーンプルから提供される人工心臓は、重度の心臓疾患に苦しむ人々にとって非常に有益なものとなると思われます。重症患者には人工心臓を設置することができます。この人工心臓は、全国の循環器専門医とIITカーンプルによって作られました。動物実験は2月か3月に開始される予定です。この研究が成功すれば、2年後には人間への移植が可能になります。患者の苦痛を和らげるために、現在、人工心臓が作られています。

この人工心臓は10人の科学者と医師のグループによって作られました。動物実験の成功を受けて、2年以内に人間への心臓移植が開始されます。末期心不全患者のために、一般に左心室補助装置（LVAD）として知られる高度な人工心臓を作るため、IITカーンプールの医学研究技術学部（SMRT）は2022年1月、Hridyantraチャレンジ・ベースのイニシアチブを設立しました。

積極的な主要プレーヤー

市場プレーヤーは、市場での事業拡大のため、製品の発売やコラボレーションなどの市場戦略を適用しています。例えば、Werfen社とMarengo Asia Hospitals社は、病院で無輸血心臓移植を可能にするために提携しました。この合意に基づき、マレンゴ・アジア・ヘルスケア・グループは、輸血を必要としない心臓移植を患者に提供するため、ワーフェンのGoal Directed Bleeding Management（GDBM）システムを使用します。患者への輸血は、困難な心臓手術の際に必要不可欠なものです。

WHOが強く勧告している患者血液管理（PBM）の信条と手順を実施することで、輸血の必要性を減らし、その結果、患者の転帰（入院期間の短縮など）を改善することができます。インドは、心臓移植の件数が飛躍的に増加していることから、南アジアにおける心臓移植の主要な紹介先となりつつあります。

新しい医療技術革新

心臓移植は、より安全に、より簡単に、より効率的に手術を行うことを目標に、医療技術革新の結果として発展しています。心臓移植におけるこうした進歩は、患者の転帰を改善し、待機期間を短縮し、臓器不足がもたらす問題に対処するために、常に変化し続けています。

2022年1月、メリーランド大学医学部とメリーランド大学医療センターによって、遺伝子を改変したブタの心臓を人に移植することに初めて成功したことが明らかにされました。この患者はメリーランド州の男性で、命を救うために画期的な手術を受け、順調に回復しているとの報告があります。

米国食品医薬品局はブタの心臓移植を許可していないが、このケースでは、医療チームによれば、患者には他の選択肢がなかったため、連邦政府は「同情的使用」としてこの処置を許可しました。

この医療技術革新は、毎年何千人もの人々が肝心の心臓移植を受けられないという臓器不足問題の解決に役立つ可能性があります。心臓移植の待機リストに載っている人の約20％は、移植を待っている間に亡くなってしまうか、病気が悪化して候補者になれなくなってしまいます。

啓発と教育

心不全について、その原因、症状、可能性のある治療法について、患者とその家族を教育することは極めて重要です。自分の心不全がどのように進行しているかを自覚している人は、医療機関を受診し、必要であれば移植のための評価を受けることができます。例えば、2021年11月、ジャスロック病院・研究センターのムンバイ拠点で「心臓移植」プログラムと部門が業務を開始しました。

最新の推計によると、心臓病はインドのナンバーワン・キラーであり、静かな伝染病です。ムンバイ市公社（BMC）のデータによると、同市では毎日90人以上が心臓発作で亡くなっています。公的記録によると、ムンバイでは過去5年間に163件の心臓移植が行われ、記録的な件数となっています。

複雑さとリスク

心臓移植の候補者を特定するためには、包括的な患者評価が必要です。患者が医学的に手術に適しているかどうかを確認するために、病歴、全身状態、合併症を評価する必要があります。レシピエントと適合するドナーの心臓を適合させることは難しいです。拒絶反応のリスクを下げるためには、血液型、組織の適合性、大きさの一致などの変数を考慮しなければならないです。

心臓移植手術に伴うリスクには、出血、感染、麻酔の問題などがあります。人によっては血管や手術の接続部に問題が生じることもあります。免疫抑制剤は臓器拒絶反応の危険性を完全に排除するものではありません。これはレシピエントの免疫系が移植された心臓を異物と認識して拒絶反応を起こすことで起こります。拒絶反応のエピソードは一過性のものかもしれないし、慢性的なものかもしれないです。

高額な費用

心臓移植の候補者は、様々な医学的検査、専門医の診察、診断手順を含む長い評価プロセスを経る。これらの検査は、患者さんの全般的な健康状態を分析し、移植に適しているかどうかを判断するために必要です。これらの評価には非常に高額な費用がかかります。

長く複雑な心臓移植手術には、高度な技術を持つ外科医、麻酔科医、看護師、その他の医療専門家からなるチーム全体が必要です。手術チーム、手術室のスペース、設備にはかなりの費用がかかります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 調査活動の活発化
      • 活発な主要プレーヤー
      • 新たな医療技術革新
      • 啓発と教育
    • 抑制要因
      • 複雑さとリスク
      • 高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 心室補助デバイス
  • 全人工心臓
  • その他

第8章 エンドユーザー別

  • 病院
  • 心臓関連施設
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Vygon
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • SynCardia Systems, LLC
  • CARMAT
  • HeartWare International Inc.
  • Calon Cardio
  • Others

第12章 付録

目次
Product Code: PH7235

Overview

Transplanting a healthy donor heart into a patient's body to replace a failing or damaged one is a difficult and life-saving medical surgery. Heart transplantation as a therapeutic option for those with end-stage heart failure or serious cardiac disease continues to advance and be successful for a number of reasons. Heart transplant recipients now enjoy better survival rates and quality of life thanks to improvements in surgical methods, immunosuppressive drugs, and post-transplant care. Both patients and healthcare professionals are motivated by the procedure's success.

The availability of donor hearts has increased as a result of efforts to enlarge the donor pool through programs including awareness campaigns for organ donation, improved methods for obtaining and preserving organs, and the utilization of donors who meet more stringent criteria. The danger of organ rejection has decreased thanks to advances in immune system knowledge and the creation of more potent immunosuppressive drugs, which have also improved transplant recipients' long-term prognoses.

Dynamics

Increasing Research Activities

Growing the scope of research being done on heart transplants has the potential to greatly enhance the results and accessibility of this life-saving treatment. Advanced organ preservation methods that extend the life of donor hearts may be developed as a result of research. The number of potential organ donors can be increased and the possibility of transplantation difficulties can be decreased.

In December 2022, an artificial heart that is ready and available from IIT Kanpur would be very beneficial to those suffering from severe cardiac issues. In critical patients, artificial hearts can be placed. This artificial heart was created by cardiologists from across the nation and IIT Kanpur. Animal trials will begin in February or March. After the study is successful, transplantation can be performed on humans in the next two years. To ease patients' pain, an artificial heart is currently being created.

This artificial heart has been constructed by a group of ten scientists and physicians. Within two years, human heart transplantation will start following the success of the animal trial. In order to create a sophisticated artificial heart, commonly known as a Left Ventricular Assist Device (LVAD), for patients with end-stage heart failure, the School of Medical Research and Technology (SMRT) of IIT Kanpur has established the Hridyantra challenge-based initiative in January 2022.

Active Major Players

The market players are applying market strategies such as product launches and collaboration for the expansion of business in the market. For instance, Werfen and Marengo Asia Hospitals have joined together to make transfusion-free heart transplants available at the hospital. In accordance with the agreement, Marengo Asia Healthcare Group will use Werfen Goal Directed Bleeding Management (GDBM) systems to provide its patients with heart transplants without the need for blood transfusions. Transfusing blood into the patient is a necessity during difficult cardiac surgery procedures.

Implementing the tenets and procedures of Patient Blood Management (PBM), which the WHO strongly advises, will reduce the need for blood transfusions and, as a result, improve patient outcomes (such as a reduction in the length of hospital stay). India is becoming the leading referral location for heart transplants in South Asia as the country's number of heart transplants has increased exponentially.

New Medical Innovation

Heart transplantation is being developed as a result of medical innovation, with the goal of making the surgery safer, easier to access, and more efficient. These advancements in heart transplantation are constantly changing in order to better patient outcomes, shorten waiting periods, and address the problems brought on by organ scarcity.

In January 2022, the first successful transplant of a genetically altered pig's heart into a person was revealed by the University of Maryland School of Medicine and the University of Maryland Medical Center. The patient, a Maryland male, underwent a ground-breaking procedure to save his life, and reports indicate that he is recovering well.

The U.S. Food and Drug Administration does not permit porcine (pig) heart transplants, but in this case, the federal agency authorized the procedure for "compassionate use" because the patient had no other options, according to the medical team.

This medical innovation could aid in resolving the organ shortage issue that prevents thousands of people from receiving vital heart transplants each year. Approximately 20% of people on the heart transplant waiting list pass away while waiting for a transplant or get too ill to be suitable candidates.

Awareness and Education

It is crucial to educate patients and their families about heart failure, its causes, symptoms, and potential treatments. People who are aware of how their heart failure is progressing may seek medical attention and, if necessary, be evaluated for a transplant. For instance, in November 2021, The 'Heart transplant' program and division began operations at Jaslok Hospital & Research Center's Mumbai location.

According to the latest estimates, heart disease is India's number one killer and a silent epidemic. According to data from the Mumbai Municipal Corporation (BMC), over 90 persons in the city pass away from heart attacks each day. According to public records, the city has had a record-breaking 163 heart transplants during the past five years.

Complexity and Risk

Comprehensive patient evaluation is required to identify candidates for cardiac transplantation. To ascertain whether the patient is medically fit for the surgery, this involves evaluating their medical history, general health, and comorbidities. It can be difficult to match a recipient with a matching donor heart. To lower the risk of rejection, variables such as blood type, tissue compatibility, and size matching must be taken into account.

Risks associated with heart transplant surgery include bleeding, infection, and issues with the anaesthetic. Some people can also have problems with the blood vessels or surgical connections. Immunosuppressive medication doesn't completely eliminate the danger of organ rejection, which occurs when the recipient's immune system rejects the transplanted heart because it perceives it as foreign. Rejection episodes might be transient or chronic, and the immunosuppressive regimen may need to be changed.

High Cost

Candidates for heart transplants go through a lengthy evaluation process that involves a range of medical testing, specialist consultations, and diagnostic procedures. These tests are required to analyze a patient's general health and decide whether they are a good candidate for transplantation. These evaluations can be very expensive.

An entire team of highly skilled surgeons, anesthesiologists, nurses, and other medical professionals are needed for the lengthy and intricate heart transplant surgery. The expenses for the surgical team, the operating room space, and the equipment are substantial.

Segment Analysis

The global heart transplant market is segmented based on type, end-user and region.

The artificial heart segment accounted for approximately 54.2% of the market share

The testing artificial heart is the first of its kind created to closely resemble the human heart. Two pumps make up the device, each of which has an atrium, a ventricle, and two mechanical valves. The theory is that by producing a more natural blood flow in this way, problems that can occur with current devices will be diminished.

In July 2023, Swedish hospital Sahlgrenska University Hospital has teamed with Scandinavian company Real Heart AB for clinical studies of their mechanical heart. The business is engaged in the creation of a total artificial heart (TAH) for implantation in heart failure patients. Its TAH features a patented design that is similar to the human heart.

Two atria and two ventricles make up the TAH's four-chamber system, which helps create a physiological blood flow pattern that resembles the body's normal circulation. The business estimates that 60 heart transplants are performed in Sweden each year, but the actual number needed is much higher.

Geographical Penetration

North America accounted for approximately 38.6% of the market share

North America has been a dominant force in the global heart transplant market. According to the American Heart Association, One or both of the heart's ventricles not working properly causes serious heart failure, which is one of the most frequent causes for a heart transplant. A patient who has had a heart transplant has the chance to have a healthy heart with healthy blood flow. If the transplant is successful, cardiac function and blood flow will be more life-sustaining and close to normal.

A new yearly record was set in 2022 with 42,888 organ transplants carried out in the United States, an increase of 3.7% from the previous year. Overall, the number of heart transplants grew by 21.5 percent (4,169 in 2022). Heart transplantation is becoming a recognized treatment for severe heart disease rather than an experimental procedure. In the United States, more than 2,000 heart transplants are carried out annually.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Heart Transplant market. Many hospitals and healthcare facilities temporarily delayed or restricted elective surgeries like heart transplants during the early stages of the pandemic. As a result, fewer heart transplant surgeries were carried out.

Due of the possibility of the virus being spread through organ donation, COVID-19 prompted questions about the safety of organ transplantation. To reduce the potential of viral transmission through donated organs, organ procurement organizations (OPOs) and transplant teams had to adopt strict testing and safety standards.

Russia-Ukraine War Impact Analysis

Doctors of medicine, particularly transplant surgeons and cardiologists, may be forced to leave the impacted areas due to the violence. This can lead to a dearth of medical specialists for heart transplants. In conflict-affected areas, organ procurement organizations (OPOs) may encounter difficulties. It can become more challenging to locate and deliver donor organs to transplant facilities, which might cause delays or cancellations of surgical procedures.

Healthcare facilities in crisis zones may redirect financial resources to meet urgent humanitarian and emergency medical requirements. This might restrict funding for specific initiatives like heart transplants.

Key Developments

  • In June 2023, Vygon, a business that specializes in the design, manufacturing, and marketing of medical solutions and devices, collaborated with Carmat, a MedTech firm that develops, produces, and sells the Aeson artificial heart.

Competitive Landscape

The major global players in the market include: Vygo, SynCardia Systems, LLC, CARMAT, HeartWare International Inc., Calon Cardio, and Others.

Why Purchase the Report?

  • To visualize the global heart transplant market segmentation based on type, end-user and region as well as understand critical commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of heart transplant market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global heart transplant market report would provide approximately 41 tables, 43 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by End-user
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Activities
      • 4.1.1.2. Active Major Players
      • 4.1.1.3. New Medical Innovation
      • 4.1.1.4. Awareness and Education
    • 4.1.2. Restraints
      • 4.1.2.1. Complexity and Risk
      • 4.1.2.2. High Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Ventricular Assisted Device*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Total Artificial Hearts
  • 7.4. Others

8. By End-user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 8.1.2. Market Attractiveness Index, By End-user
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Institutes
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Vygon*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. SynCardia Systems, LLC
  • 11.3. CARMAT
  • 11.4. HeartWare International Inc.
  • 11.5. Calon Cardio
  • 11.6. Others

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us